Teva gets FDA approval for cancer drug Israel's Teva Pharmaceutical Industries said the U.S. Food and Drug Administration approved an injectable and infusion version of its cancer drug bendamustine.The drug, sold under the brand name Bendeka, is approved for treating cancer patients with chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. Teva, which has licensed the drug from Eagle Pharmaceuticals Inc, is responsible for all U.S. commercial activities for Bendeka. (Reporting by Shailesh Kuber; Editing by Saumyadeb Chakrabarty)
Family holds funeral for Florida man killed by plainclothes officer
UPDATE 4-U.S. fines Takata, bans ammonium nitrate in its air bags
Abortion provider Planned Parenthood sues Kansas over plan to cut funding